Drug Profile
Befotertinib - InventisBio
Alternative Names: Befotertinib mesylate - InventisBio; BPI-D0316; D 0316; SemenaLatest Information Update: 12 Aug 2023
Price :
$50
*
At a glance
- Originator InventisBio
- Developer Betta Pharmaceuticals Co Ltd; InventisBio
- Class Amides; Amines; Antineoplastics; Dimethylamines; Fluorinated hydrocarbons; Indoles; Mesylates; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 11 Aug 2023 Chemical structure information added
- 09 Aug 2023 First global launch - Launched for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
- 09 Aug 2023 Preregistration for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO) (Betta Pharmaceuticals pipeline, August 2023)